Galmed Pharmaceuticals
GLMD
14 hedge funds and large institutions have $3.13M invested in Galmed Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
27% more capital invested
Capital invested by funds: $2.47M → $3.13M (+$666K)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$597K |
| 2 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$253K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$66.4K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$48.3K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$30.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$224K |
| 2 |
CAD
Craig A. Drill
|
-$90K |
| 3 |
Renaissance Technologies
New York
|
-$49K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$23K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$23K |
GLMD Hedge Fund Activity: Q3 2016 in Review
14 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2016, worth a combined $3.13M — up 27% from $2.47M a quarter earlier.
Fund positioning in GLMD was balanced in Q3 2016: 5 funds opened new positions, 5 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $597K. The largest seller was Knoll Capital Management, exiting entirely with an estimated $224K sold.
- 14 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $3.13M of Galmed Pharmaceuticals stock for Q3 2016, up 27% quarter-over-quarter.
- 5 funds opened new Galmed Pharmaceuticals positions in Q3 2016 and 5 closed out, a net change of 0 holders.
- The largest Galmed Pharmaceuticals buyer in Q3 2016 was 683 Capital Management, an estimated $597K added.
- The largest Galmed Pharmaceuticals seller in Q3 2016 was Knoll Capital Management, an estimated $224K sold.
Based on aggregated 13F filings for Q3 2016.